INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Yahoo · 14 de sept de 2026
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
CEDEAR NVS
Novartis Ag
Sí, existe CEDEAR de NVS en Argentina. Operás bajo el ticker NVS en BYMA, con ratio 4:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareDrug Manufacturers - General
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- País
- Switzerland
- Empleados
- 75.267
- Sitio web
- novartis.com
Precio histórico
Últimos 202 días · 13/11/25 — 14/09/26
+13.31%
Cotización y datos
NYSERatio 4:1 · Subyacente NVS
CEDEAR (ARS)
Precio
$ 55.350
Var. %
-0,22%
Volumen operado
1.426
Subyacente (USD)
Precio NVS
US$ 138,87
Teórico (precio / ratio)
NVS ÷ 4
US$ 34,72
Dólar MEP (NVSD)
Preguntas frecuentes
¿Existe CEDEAR de NVS en Argentina?
Sí, existe el CEDEAR de NVS (Novartis Ag) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es NVS.
¿Cuál es el ticker del CEDEAR de Novartis Ag?
El ticker del CEDEAR de Novartis Ag en Argentina es NVS. La acción subyacente cotiza en NYSE con el símbolo NVS.
¿Cuál es el ratio del CEDEAR NVS?
El CEDEAR NVS tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de NVS.
¿Cuánto vale el CEDEAR NVS hoy?
El CEDEAR NVS cotiza hoy a $ 55.350 en pesos argentinos, con una variación diaria de -0,22%.
¿Cuánto vale la acción NVS en dólares?
La acción subyacente NVS (Novartis Ag) cotiza a US$ 138,87 en su mercado de origen (NYSE).
Noticias
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
Yahoo · 14 de sept de 2026
The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding…
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
Yahoo · 14 de sept de 2026
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.